Literature DB >> 15140466

Growth factor pre-treatment differentially regulates phosphoinositide turnover downstream of lysophospholipid receptor and metabotropic glutamate receptors in cultured rat cerebrocortical astrocytes.

Tadimeti S Rao1, Karen D Lariosa-Willingham, Fen-Fen Lin, Naichen Yu, Chui-Se Tham, Jerold Chun, Michael Webb.   

Abstract

Reactive gliosis is an aspect of neural plasticity and growth factor (GF) stimulation of astrocytes in vitro is widely regarded as a model system to study astrocyte plasticity. Astrocytes express receptors for several ligands including lysophosphatidic acid (LPA) and sphingosine-1-phosphate (S1P), agonists for the G-protein-coupled lysophospholipid receptors (lpRs). Activation of lpRs by LPA or S1P leads to multiple pharmacological effects including the influx of calcium, phosphoinositide (PI) hydrolysis, phosphorylation of extracellular receptor regulated kinase (ERK), release of arachidonic acid, and induces mitogenesis. Treatment of astrocytes in vitro with a growth factor cocktail (containing epidermal growth factor [EGF], basic fibroblast growth factor [bFGF] and insulin) led to a marked attenuation of lpR-induced PI hydrolysis. In contrast, under identical conditions, GF treatment led to marked potentiation of PI hydrolysis downstream of activation of another abundantly expressed G-protein coupled receptor, mGluR5. Quantitative gene expression analysis of GF-treated or control astrocytes by TaqMan RT-PCR indicated that GF treatment did not change gene expression of lpa1 and s1p1, but increased gene expression of s1p5 which is expressed at very low levels in basal conditions. These results suggest that GF differentially affected PLC activation downstream of mGluR5 versus lpR activation and that the changes in mRNA levels of lpRs do not account for marked attenuation of agonist-induced phosphoinositide turnover. Copyright 2004 ISDN

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15140466     DOI: 10.1016/j.ijdevneu.2004.03.005

Source DB:  PubMed          Journal:  Int J Dev Neurosci        ISSN: 0736-5748            Impact factor:   2.457


  13 in total

Review 1.  Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors.

Authors:  Victoria A Blaho; Timothy Hla
Journal:  Chem Rev       Date:  2011-09-22       Impact factor: 60.622

2.  Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices.

Authors:  Veronique E Miron; Samuel K Ludwin; Peter J Darlington; Andrew A Jarjour; Betty Soliven; Timothy E Kennedy; Jack P Antel
Journal:  Am J Pathol       Date:  2010-04-22       Impact factor: 4.307

Review 3.  Phosphoinositide pathway and the signal transduction network in neural development.

Authors:  Vincenza Rita Lo Vasco
Journal:  Neurosci Bull       Date:  2012-11-14       Impact factor: 5.203

Review 4.  Regulation of human glia by multiple sclerosis disease modifying therapies.

Authors:  Luke M Healy; Mackenzie A Michell-Robinson; Jack P Antel
Journal:  Semin Immunopathol       Date:  2015-08-11       Impact factor: 9.623

Review 5.  Lysophospholipids and their receptors in the central nervous system.

Authors:  Ji Woong Choi; Jerold Chun
Journal:  Biochim Biophys Acta       Date:  2012-07-31

Review 6.  Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.

Authors:  Jerold Chun; Hans-Peter Hartung
Journal:  Clin Neuropharmacol       Date:  2010 Mar-Apr       Impact factor: 1.592

Review 7.  Role of Ca2+-independent phospholipase A2 in cell growth and signaling.

Authors:  Shelley B Hooks; Brian S Cummings
Journal:  Biochem Pharmacol       Date:  2008-08-15       Impact factor: 5.858

Review 8.  Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy.

Authors:  Aran Groves; Yasuyuki Kihara; Jerold Chun
Journal:  J Neurol Sci       Date:  2013-03-19       Impact factor: 3.181

Review 9.  S1P/S1P Receptor Signaling in Neuromuscolar Disorders.

Authors:  Elisabetta Meacci; Mercedes Garcia-Gil
Journal:  Int J Mol Sci       Date:  2019-12-17       Impact factor: 5.923

Review 10.  FTY720 (Fingolimod) Ameliorates Brain Injury through Multiple Mechanisms and is a Strong Candidate for Stroke Treatment.

Authors:  Zifeng Wang; Masahito Kawabori; Kiyohiro Houkin
Journal:  Curr Med Chem       Date:  2020       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.